Skip to main content
Celalettin Ustun, MD, Oncology, Chicago, IL, Rush University Medical Center

CelalettinUstunMD

Oncology Chicago, IL

Hematologic Oncology

Associate Professor, Medicine, University of Minnesota Medical School

Dr. Ustun is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ustun's full profile

Already have an account?

Education & Training

  • Medical College of Georgia
    Medical College of GeorgiaFellowship, Hematology and Medical Oncology, 2005 - 2006
  • Vidant Medical Center/East Carolina University
    Vidant Medical Center/East Carolina UniversityResidency, Internal Medicine, 2002 - 2005
  • Medical College of Georgia
    Medical College of GeorgiaFellowship, Hematology and Medical Oncology, 2000 - 2002
  • Ankara University FOM
    Ankara University FOMClass of 1990

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2018 - 2026
  • IN State Medical License
    IN State Medical License 2023 - 2023
  • MN State Medical License
    MN State Medical License 2010 - 2019
  • GA State Medical License
    GA State Medical License 2005 - 2011
  • NC State Medical License
    NC State Medical License 2002 - 2006
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment Kinetics  
    Erhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica

Lectures

  • Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Higher Stakes in Systemic Mastocytosis​
    Higher Stakes in Systemic Mastocytosis​June 18th, 2021
  • Nonmyeloablative Conditioning Carries Lowers Infection Risk in Patients with AML
    Nonmyeloablative Conditioning Carries Lowers Infection Risk in Patients with AMLSeptember 10th, 2019

Hospital Affiliations